Field study for validating an optimized dual-test for cannabinoids in urine for a more efficient determination of cases regarding legislation (§ 24a StVG);Feldstudie zur validierung eines optimierten doppelstreifentestes für cannabinoide im urin zur effizienteren erfassung von fällen des § 24a StVG

Blutalkohol

Volumn 44, Issue 6, 2007, Pages 345-359

  Lott, Susanne ^a,b   Protzek, Christoph ^c   Aderjan, Rolf ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PHYSIKALISCH TECHNISCHE BUNDESANSTALT   (Germany)

^c Gesellschaft für Biomedizinische Technik mbH   (Germany)

^d Institut für Rechts und Verkehrsmedizin   (Germany)

Author keywords

Cannabinoids; Law infringements; Road traffic; Urine road side test

Indexed keywords

CANNABINOID; CANNABIS; TETRAHYDROCANNABINOL;

ARTICLE; CANNABIS ADDICTION; CAR DRIVING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; LAW; URINALYSIS;

EID: 36949032922     PISSN: 00065250     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Aderjan R. Beurteilungskriterien der Kraftfahreignung aus toxikologischer Sicht. Berichte der Bundesanstalt für Straßenwesen 2003;152:189-200
2. Ellis G M, Mann M A, Judson B A, Schramm N T, Tashchian A. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985; 38: 572-8
3. Glaz-Sandberg A, Dietz L, Nguyen H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-9-carboxy-Delta (9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther. 2007 Jul; 82 (1): 63-9
4. Gustafson R A, Kim I, Stout P R, Klette K L, George M P, Moolchan E T, et al. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J Anal Toxicol 2004; 28: 160-7
5. Huestis M A, Cone E J. Urinary Excretion Half-Life of 11-Nor-9-carboxy-[DELTA]9-tetrahydrocannabinol in Humans. Ther Drug Monit 1998; 20: 570-6
6. Huestis M A, Cone E J. Differentiating New Marijuana Use from Residual Drug Excretion in Occasional Marijuana Users, J Anal Toxicol 1998; 22: 445-54
7. Johansson E, Halldin M, Agurell S, Hollister L E, Gillespie H K. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989; 37: 273-7
8. Leighty E G, Fentiman A F, Jr., Foltz R L. Long-retained metabolites of delta9- and delta8-tetrahydrocannabinols identified as novel fatty acid conjugates. Research communications in chemical pathology and pharmacology 1976; 14: 13-28
9. Nahas G, Leger C, Tocque B, Hoellinger H. The kinetics of cannabinoid distribution and storage with special reference to the brain and testis. Journal of clinical pharmacology 1981; 21: 208S-214S
10. Skopp G, Richter B, Pötsch L. Cannabinoidbefunde im Serum 24 bis 48 Stunden nach Rauchkonsum. Arch Kriminol 2003; 212: 83-95
11. Skopp G, Pötsch L, Ganámann B, Mauden M, Richter B, Aderjan R, Mattern R. Freie und glucuronidierte Cannabinoide im Urin - Untersuchungen zur Einschätzung des Konsumverhaltens. Rechtsmedizin 1999; 10: 21-8
12. Wall M E, Perez-Reyes M. The metabolism of delta 9 Tetrahydrocannabinol and Related Cannabinoids in Man. J Clin Pharmacol 1981; 21: 178-89